The impact of macular pigment augmentation on visual performance using different carotenoid formulations

Invest Ophthalmol Vis Sci. 2012 Nov 29;53(12):7871-80. doi: 10.1167/iovs.12-10690.

Abstract

Purpose: To investigate changes in macular pigment optical density (MPOD) and visual performance following supplementation with different macular carotenoid formulations.

Methods: Thirty-six subjects (19 male, 17 female; mean SD, age 51 13 years) were recruited into this single-masked placebo-controlled study, and were randomly assigned to one of the following three intervention (supplementation) groups: (1) group 1 (20 mg lutein [L] and 2 mg zeaxanthin [Z]); (2) group 2 (10 mg L, 2 mg Z, and 10 mg meso-zeaxanthin [MZ]); and group 3 (placebo). Outcomes measures included visual performance and MPOD response. Data were collected at baseline, at 3 months, and at 6 months.

Results: At 3 and 6 months, a statistically significant increase in MPOD was found at all eccentricities (other than the most peripheral 3° location) in group 2 (P < 0.05 for all), whereas no significant increase in MPOD was demonstrable at any eccentricity for subjects in groups 1 and 3. Statistically significant improvements in visual performance measures including visual acuity and contrast sensitivity with and without glare were observed for group 2 only. Only mesopic contrast sensitivity at one spatial frequency improved significantly by 6 months (P < 0.05) for group 1. No improvements in any parameters of visual performance were observed for subjects supplemented with placebo (P > 0.05 for all).

Conclusions: These results suggest that supplementation with all three macular carotenoids potentially offered advantages over preparations lacking MZ, both in terms of MPOD response and visual performance enhancement.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antioxidants / therapeutic use
  • Carotenoids / therapeutic use*
  • Dietary Supplements*
  • Female
  • Follow-Up Studies
  • Humans
  • Macula Lutea / drug effects
  • Macula Lutea / pathology*
  • Macular Degeneration / drug therapy*
  • Macular Degeneration / pathology
  • Macular Degeneration / physiopathology
  • Male
  • Middle Aged
  • Prospective Studies
  • Retinal Pigment Epithelium / drug effects
  • Retinal Pigment Epithelium / pathology*
  • Single-Blind Method
  • Treatment Outcome
  • Visual Acuity*
  • Young Adult

Substances

  • Antioxidants
  • Carotenoids